Sign in
CompletedNo phase

The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

Key facts

Who runs it
Nanfang Hospital, Southern Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,000 people enrolled
Started
1 Jan 2018
Ended
1 Dec 2025
Type of study
Observational, 2 groups
Treatments tested
  • 2018 edition of the Guidelines for Diagnosis
Record updated
1 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Voluntary signing of informed consent form
  • When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender
  • From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination

Who cannot take part

  • Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement
  • Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction
  • Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation
  • Patients deemed unsuitable for participation in this study by the researchers

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmonary embolism group and non pulmonary embolism group. 1. Collect relevant data, including gender, age, primary disease, CTPA imaging and reports, BNP, troponin, electrocardiogram, cardiac ultrasound, PT, APTT, TT, fibrinogen, D-dimer, etc., and analyze demographic data, pulmonary embolism risk grading, APTT/fibrinogen ratio, and determine their cut-off values through statistical analysis of the two groups. 2. Follow up on the APTT/fibrinogen ratio after anticoagulation treatment and bleeding in the pulmonary embolism group.

The 2 groups in the trial

  • Patients with acute pulmonary embolism

    Treatment: 2018 edition of the Guidelines for Diagnosis

  • Patients without acute pulmonary embolism

    Treatment: 2018 edition of the Guidelines for Diagnosis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
1 July 2026